High-dose estrogen therapy (HDE) is a type of hormone therapy in which high doses of estrogens are given. When given in combination with a high dose of progestogen, it has been referred to as pseudopregnancy. It is called this because the estrogen and progestogen levels achieved are in the range of the very high levels of these hormones that occur during pregnancy. HDE and pseudopregnancy have been used in medicine for a number of hormone-dependent indications, such as breast cancer, prostate cancer, and endometriosis, among others. Both natural or bioidentical estrogens and synthetic estrogens have been used and both oral and parenteral routes may be used.
Medical uses HDE and/or pseudopregnancy have been used in clinical medicine for the following indications:
Estrogen receptor-positive breast cancer in women As a means of androgen deprivation therapy for prostate cancer and benign prostatic hyperplasia in men In combination with progestins for endometriosis in women. Although initially used alone, progestins were added in the 1960s and 1970s. In addition, the estrogen diethylstilbestrol is an example of medical reversal as it increases the risk of endometriosis in the treated women and in their female children. Osteopenia and osteoporosis in women Prevention of tall stature in tall adolescent girls Suppression of IGF-1Tooltip insulin-like growth factor 1 levels in acromegaly and gigantism As a component of hormone therapy for transgender women to achieve feminization and suppress androgens Breast hypoplasia or as a means of hormonal breast enhancement in women Uterine hypoplasia in women Premenstrual syndrome and premenstrual dysphoric disorder in women Postpartum depression and psychosis in women The nonsteroidal estrogen diethylstilbestrol as well as other stilbestrols were previously used to support pregnancy and reduce the risk of miscarriage, but subsequent research found that diethylstilbestrol was both ineffective and teratogenic. HDE should be combined with a progestogen in women with an intact uterus as unopposed estrogen, particularly at high dosages, increases the risk of endometrial hyperplasia and endometrial cancer. The majority of women with an intact uterus will develop endometrial hyperplasia within a few years of estrogen treatment even with mere replacement dosages of estrogen if a progestogen is not taken concomitantly. The addition of a progestogen to estrogen abolishes the increase in risk.
Available forms The following steroidal estrogens have been used in HDE therapy:
Conjugated estrogens (Premarin) Estradiol and estradiol esters (e.g., estradiol benzoate, estradiol undecylate, estradiol valerate, polyestradiol phosphate) Estramustine phosphate (an estradiol ester that is also a cytostatic antineoplastic agent; used for prostate cancer only) Ethinylestradiol, its ether mestranol, and its ester ethinylestradiol sulfonate As well as the following nonsteroidal estrogens (which are now little or not at all used):
Diethylstilbestrol (stilbestrol), fosfestrol (diethylstilbestrol diphosphate), bifluranol, and other stilbestrols Progestogens that have been used in pseudopregnancy regimens include hydroxyprogesterone caproate, medroxyprogesterone acetate, and cyproterone acetate, among others. Progesterone has been little-used for such purposes likely due to its poor pharmacokinetics (e.g., low oral bioavailability and short elimination half-life).
Side effects
General adverse effects of HDE may include breast enlargement, breast pain and tenderness, nipple enlargement and hyperpigmentation, nausea and vomiting, headache, fluid retention, edema, melasma, hyperprolactinemia, galactorrhea, amenorrhea, reversible infertility, and others. More uncommon but serious side effects may include thrombus and thrombosis (e.g., venous thromboembolism), other cardiovascular events (e.g., myocardial infarction, stroke), prolactinoma, cholestatic jaundice, gallbladder disease, and gallstones. In women, HDE may cause amenorrhea and rarely endometrial hyperplasia or endometrial cancer, but the risk of adverse endometrial changes is minimized or offset with pseudopregnancy regimens due to the progestogen component. The tolerability profile of HDE is worse in men compared to women. Side effects of HDE specific to men may include gynecomastia (breast development), feminization and demasculinization in general (e.g., reduced body hair, decreased muscle mass and strength, feminine changes in fat mass and distribution, and reduced penile and testicular size), and sexual dysfunction (e.g., reduced libido and erectile dysfunction). The use of HDE in men has been associated with cellulite, which has been attributed to androgen deficiency.
Pharmacology
… excerpt ends here. Continue reading the full article.


